When was Bonti founded?

Bonti was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Bonti located?

Bonti is headquartered in Newport Beach, United States.

Who is the current CEO of Bonti?

Fauad Hasan of Bonti. They have also founded 1 company.

How many employees does Bonti have?

As of Jul 01, 2024, the latest employee count at Bonti is 11 - 50.

Is Bonti a funded company?

Bonti is a funded company, having raised a total of $36M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 15, 2015.

When was the latest funding round of Bonti?

Bonti's latest funding was a $***** Series C round on Jan 23, 2018, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.15B in funding in 2026 to date.

Where does Bonti rank among its competitors?

Bonti ranks 503rd amongst 2746 active competitors, of which 917 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Bonti?

Bonti's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and argenx. Among them, Immuneel secured the most recent funding round in June, 2026.

Bonti - 2026 Company Profile, Team, Funding & Competitors

Q: Is Bonti an acquired company?

Bonti got acquired by Allergan on Sep 14, 2018.

Bonti is an acquired company based in Newport Beach (United States), founded in 2015 by Fauad Hasan and Susan Abushakra. It operates as a Developing botulinum neurotoxins for the treatment of musculoskeletal pain. Bonti has raised $36M in funding from investors like City Hill, RBV Capital and Viva Ventures Biotech Fund. The company has 2746 active competitors, including 917 funded and 691 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and argenx.

Company Details

Developing botulinum neurotoxins for the treatment of musculoskeletal pain. It is a clinical-stage company focused on developing neurotoxins for therapeutic & aesthetic applications using its proprietary platform. Its lead drug EB-001 is a novel serotype E botulinum neurotoxin (BoNT/E) being developed for the treatment of post-surgical and non-surgical musculoskeletal pain. EB-001 acts on muscle hyperactivity which is the main cause of musculoskeletal pain.

Key Metrics

Founded Year

2015

Location

Newport Beach, United States

Stage

Acquired

Total Funding

$36M in 5 rounds

Latest Funding Round

Series C, Jan 23, 2018, $*****

Investors

City Hill & 8 more

Ranked

503^rd among 2746 active competitors

Employee Count

11 - 50 as on Jul 01, 2024

Similar Companies

Heron Therapeutics & 311 more

Exit Details

Acquired by Allergan (Sep 14, 2018)

View Bonti's full profile

Bonti got acquired by Allergan on Sep 14, 2018 at an acquisition amount of $*****.

Click here to take a look at Bonti's acquisition in detail

Bonti has raised a total funding of $36M over 5 rounds. Its first funding round was on Sep 15, 2015. Its latest funding round was a Series C round on Jan 23, 2018 for $*****. 1 investor participated in its latest round. Bonti has 9 institutional investors.

Here is the list of recent funding rounds of Bonti:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 23, 2018	7619066	Series C	5289551	1271068	6590731	2100843
2017	8952	Series B	3189	9677	2838	9663
Apr 18, 2017	4806447	Series B	5549223	6049126	RBV Capital	City Hill & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Bonti's funding rounds and investors

The founders of Bonti are Fauad Hasan and Susan Abushakra.

Here are the details of Bonti's key team members:

Fauad Hasan: Co-Founder & CEO of Bonti and founder of 2 other companies, Ornovi and Dev Academy. They serve on the board of 1 company.
Contact Info: 1 email address
Susan Abushakra: Co-Founder & CMO of Bonti and founder of 1 other company.

View details of Bonti's Founder profiles and Board Members

Bonti's employee count trend

Bonti has 11 - 50 employees as of Jul 24. Here is Bonti's employee count trend over the years:

Uncover Bonti's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bonti include Jazz Pharmaceuticals, Sana Biotechnology and argenx. Here is the list of Top 10 competitors of Bonti, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
503rd	Bonti 2015, Newport Beach (United States), Acquired	Developing botulinum neurotoxins for the treatment of musculoskeletal pain	$36M	Colt Ventures, SVB & 7 others	49/100